clinical trial · NCT07678970
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.·phase1·not yet recruiting·n = 10
Gastrointestinal TumorSolid TumorSI-B036
brief summary
This study is an open-label, multicenter, non-randomized Phase I clinical study with dose-escalation and expansion cohorts, designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of SI-B036 bispecific antibody injection in patients with locally advanced or metastatic gastrointestinal tumors and other solid tumors.
started
Jul 1, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Jul 16, 2026
detailed description
The study consists of two phases: a dose-escalation phase (Phase Ia) and an expansion cohort phase (Phase Ib).
official title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SI-B036 Bispecific Antibody Injection in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol